Saturday 17 October 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.73
0.23
−11.73%
Follow PACB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 5 | 4 |
| (205.90%) | (213.45%) | (273.55%) | (929.31%) | ||
| (44.70%) | (53.45%) | (15.65%) | (16.66%) | ||
ROIC |
(108.83%) | (93.25%) | 0.00% | (22.22%) | |
Return on Tangible Assets |
(142.61%) | (167.41%) | (39.14%) | (44.27%) | |
Average Days of Receivables |
72.29 | 80.86 | 66.94 | 71.28 | |
Free Cash Flow per Share |
(0.44) | (0.40) | (0.23) | (0.26) | |
Free Cash Flow |
(131.44) | (118.92) | (71.21) | (80.48) | |
Capital Expenditures |
(8.65) | (7.71) | 40.63 | 37.57 | |
| Other line items | |||||
Cash ROIC |
(13.41%) | (12.78%) | (25.58%) | (9.49%) | |
Accounts Receivable Turnover |
5.15 | 5.08 | 5.25 | 5.03 | |
Accounts Payable Turnover |
8.11 | 6.11 | 7.24 | 5.91 | |
Inventory Turnover |
1.94 | 2.11 | 1.91 | 1.76 | |
Average Days of Payables |
51.79 | 66.37 | 49.65 | 69.25 | |
Days of Inventory on Hand |
168.25 | 157.49 | 186.16 | 220.04 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
65.91% | 60.81% | 54.90% | 55.47% | |
Selling, General and Administrative Expense of Revenue |
96.44% | 88.43% | 82.78% | 81.43% | |
Share Based Compensation of Revenue |
31.12% | 26.04% | 23.07% | 21.53% | |
Interest Coverage |
(83.51) | (79.65) | (19.16) | (18.15) | |
Operating CF/Net income |
0.24 | 0.20 | 0.87 | 0.90 | |
Depreciation/Fixed assets |
22.27 | 16.44 | 0.61 | 0.58 | |
Capex/Depreciation |
(0.02) | (0.02) | 2.76 | 2.39 | |
Revenue per Share |
0.51 | 0.53 | 0.52 | 0.51 | |
Operating CF per Share |
(0.41) | (0.37) | (0.37) | (0.38) | |
Capex per Share |
(0.03) | (0.03) | 0.13 | 0.12 | |
Capex to Sales |
0.06 | 0.05 | (0.25) | (0.24) |
Columns are period end dates